healthy subjects
Conditions
Interventions
Subjects receive 250 mg/day of NMN for 12 weeks.
Subjects receive placebo for 12 weeks.
Sponsors
Department of Diabetes and Metabolic Diseases, The University of Tokyo Hospital
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1)the healthy subjects who agree to the study. 2)Body Mass Index 22-28 3)no smoking history
Exclusion criteria
Exclusion criteria: 1)The subjects who take functional food that may affect the trial 2)The subjects who take more than one hour daily exercise for more than 6 months 3)The subjects with the history of serious disease (malignant neoplasms, cardiac failure and myocardial infarction ) 4)The subjects with chronic disease 5)The subjects who take medicines 6)The subjects with allergic disorders. 7)The subjects who participate in any clinical trial within 90 days of the commencement of the trial 8)The subjects judged as ineligible by clinical investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the skeletal muscle index by the bioelectrical impedance analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To evaluate the parameters related to glucose metabolism 2)To evaluate the vascular endothelial function by FMD | — |
Countries
Japan
Contacts
Public ContactMasaki Igarashi
The University of Tokyo Hospital Department of Diabetes and Metabolic Diseases
Outcome results
None listed